Evidence map›Paper›PMID 37390335›Full record

ArticleAging2023

Identification of prognosis value and immune microenvironment features of ceRNAs in NSCLC with distinct gene mutation.

Jiangtao You, Qingshi Wang, Longlong Cong, Rui Zhao, Wei Cui, Huan Chen

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jiangtao YouDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi, China.
Qingshi WangDepartment of Surgical Oncology, The First People’s Hospital of Xianyang City, Xianyang, Shanxi, China.
Longlong CongDepartment of Vascular Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi, China.
Rui ZhaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi, China.
Wei CuiDepartment of Endocrinology and Second Department of Geriatrics, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi, China.
Huan ChenDepartment of Endocrinology and Second Department of Geriatrics, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi, China.
First Affiliated Hospital of Xi'an Jiaotong University · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC), representing about 85% of all lung cancer (LC) cases, is by far the most common form of LC. High-throughput technology largely expands our ability to analyze the transcriptome data and a plethora of cancer-driving genes has been identified, paving the path to immune therapy, where the effects of cancer-causing mutations are countered with microenvironment complexity. Given that competing endogenous RNAs (ceRNAs) participate in diverse cellular processes by a broad array of mechanisms in cancer, we scrutinized the immune microenvironment and ceRNA signatures in mutation-specific NSCLC by integrating TCGA-NSCLC and NSCLS-associated GEO datasets. The results suggested that RASA1mutation clusters in LUSC had a better prognosis and immunity. Immune cell infiltration analysis indicated that the cluster with RASA1 mutation had a significantly high level of NK T cells and a low level of memory effector T cells. Further analysis of immune-related ceRNAs in LUSC showed that hsa-miR-23a was significantly associated with survival in RASA1-mutation samples, indicating that there may be specific ceRNAs in mutation-specific subgroups in NSCLC. In conclusion, this study verified the presence of complexity and diversity of NSCLC gene mutations and highlighted the intricate links between gene mutation and tumor environment features.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsGTPase-Activating ProteinsHumansMutationOncogenesp120 GTPase Activating ProteinPrognosisTumor MicroenvironmentGTPase-Activating Proteinsp120 GTPase Activating ProteinRASA1 protein, humanceRNAimmunemutationNSCLCprognosis

Identifiers

PMID37390335
PMCPMC10333077
OpenAlexW4382139200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.